Byoung S. Kwon
Founder and CEO
Dr. Kwon had his PhD from the Georgia Regents University, in 1981 and postdoctoral studies at the Department of Human Genetics, Yale University from 1981 to 1984. Dr. Kwon was a tenured Professor of the Indiana University School of Medicine, a Professor and Director of the Immunomodulation Research Center at the University of Ulsan, a Distinguished Professor and Investigator at the National Cancer Center, Korea, and Professor at the Department of Medicine Tulane University, New Orleans LA . He is currently the Founder and CEO of Eutilex who is developing T cell therapeutics and immunomodulatory antibody therapeutics. He has published over 300 peer-reviewed papers and has been serving as an editorial member of reputable journals.
Dr. Kwon’s research focuses on immunotherapy against cancers and autoimmune diseases. Dr. Kwon has established a concept called “inducible costimulation” by discovering 4-1BB-4-1BBL and AITR-AITRL systems. He has proved that immune functions can be selectively suppressed or enhanced through the inducible costimulation and presented the possibility of “selective immunotherapy”. Antigen-specific T cell therapeutics that Dr. Kwon’s team has developed are in phase 1 trials against various cancers in the NCC.